Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1547
Abstract: We predicted the drug–drug interaction (DDI) potential of siponimod in presence of cytochrome P450 (CYP)2C9/CYP3A4 inhibitors/inducers in subjects with different CYP2C9 genotypes by physiologically‐based pharmacokinetic (PK) modeling. The model was established using in vitro and… read more here.
Keywords: siponimod; drug interaction; potential siponimod; drug ... See more keywords
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2078103
Abstract: Abstract Objective Identification of the phenotypic transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is often delayed due to disease complexity and an unwillingness to withdraw RRMS disease-modifying therapies (DMTs), driven… read more here.
Keywords: cost; treatment; multiple sclerosis; siponimod ... See more keywords
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s122249
Abstract: Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared… read more here.
Keywords: siponimod; treatment; evidence; multiple sclerosis ... See more keywords
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
Sign Up to like & getrecommendations! Published in 2022 at "Patient preference and adherence"
DOI: 10.2147/ppa.s221882
Abstract: Introduction A number of disease-modifying therapies have been approved for use in relapsing-remitting multiple sclerosis (MS) in the past two decades. However, only few treatment options are available for patients with secondary progressive multiple sclerosis… read more here.
Keywords: progressive multiple; secondary progressive; efficacy safety; multiple sclerosis ... See more keywords